Bruderman Asset Management’s Haemonetics HAE Stock Holding History

Bruderman Asset Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,175	Closed	-$41K	–	383
2016 Q1	$41K	Hold	1,175	–	–	0.01%	212
2015 Q4	$38K	Hold	1,175	–	–	0.01%	234
2015 Q3	$38K	Buy	1,175 +70	+6%	+$2.63K	0.02%	231
2015 Q2	$46K	Sell	1,105 -320	-22%	-$13.5K	0.02%	229
2015 Q1	$64K	Buy	+1,425	New	+$59.6K	0.03%	189

Other funds holding HAE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.78B AUM 5.83% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

VBA

Van Berkom & Associates Montreal, Quebec, Canada $3.1B AUM 12.88% 1-Year Est. Return

Bruderman Asset Management's HAE Position: Q2 2016 in Review

Bruderman Asset Management sold out of Haemonetics (HAE) in Q2 2016, closing a stake of 1,175 shares — an estimated $41K sold.

Bruderman Asset Management first reported a position in HAE in Q1 2015 and held it in 5 quarters. The position peaked at $64K in Q1 2015. 178 funds tracked by Wall St. Rank hold HAE as of Q2 2016.

Bruderman Asset Management reported no remaining Haemonetics position as of Q2 2016 after selling out during the quarter.
Bruderman Asset Management sold 1,175 Haemonetics shares in Q2 2016, an estimated $41K.
Bruderman Asset Management first reported a position in Haemonetics in Q1 2015 and held it in 5 quarters.
Bruderman Asset Management's Haemonetics position peaked at $64K in Q1 2015.
178 funds tracked by Wall St. Rank held Haemonetics as of Q2 2016.

Based on Bruderman Asset Management's 13F filing for Q2 2016, filed 9 Aug 2016.